Abstract
Pervasive developmental disorders (PDDs) are severe developmental disabilities defined by behavioral criteria. Our present understanding of the neurobiological basis of this disorder is limited. Clinicians treating children with PDDs must be aware of the varying severity of manifestations and the lifelong nature of this disorder. The current clinical role of pharmacotherapy in the management of PDDs is to ameliorate behavioral symptoms that are interfering with the individual's ability to participate in educational, social and family systems. In this paper we review some of the medications which have shown positive effects in the treatment of children with PDDs.
| Original language | English |
|---|---|
| Pages (from-to) | 211-218 |
| Number of pages | 8 |
| Journal | International Pediatrics |
| Volume | 8 |
| Issue number | 2 |
| State | Published - Jan 1 1993 |
Fingerprint
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health
Cite this
Pharmacotherapy of pervasive developmental disorders. / Tuchman, R.; Gilman, J.
In: International Pediatrics, Vol. 8, No. 2, 01.01.1993, p. 211-218.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Pharmacotherapy of pervasive developmental disorders
AU - Tuchman, R.
AU - Gilman, J.
PY - 1993/1/1
Y1 - 1993/1/1
N2 - Pervasive developmental disorders (PDDs) are severe developmental disabilities defined by behavioral criteria. Our present understanding of the neurobiological basis of this disorder is limited. Clinicians treating children with PDDs must be aware of the varying severity of manifestations and the lifelong nature of this disorder. The current clinical role of pharmacotherapy in the management of PDDs is to ameliorate behavioral symptoms that are interfering with the individual's ability to participate in educational, social and family systems. In this paper we review some of the medications which have shown positive effects in the treatment of children with PDDs.
AB - Pervasive developmental disorders (PDDs) are severe developmental disabilities defined by behavioral criteria. Our present understanding of the neurobiological basis of this disorder is limited. Clinicians treating children with PDDs must be aware of the varying severity of manifestations and the lifelong nature of this disorder. The current clinical role of pharmacotherapy in the management of PDDs is to ameliorate behavioral symptoms that are interfering with the individual's ability to participate in educational, social and family systems. In this paper we review some of the medications which have shown positive effects in the treatment of children with PDDs.
UR - http://www.scopus.com/inward/record.url?scp=0027203095&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027203095&partnerID=8YFLogxK
M3 - Article
VL - 8
SP - 211
EP - 218
JO - International Pediatrics
JF - International Pediatrics
SN - 0885-6265
IS - 2
ER -